efavirenz nightmare profile
Selected indexed studies
- Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. (N Engl J Med, 2013) [PMID:24195548]
- Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events. (Ann Pharmacother, 2014) [PMID:24259633]
- Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom. (AIDS Res Hum Retroviruses, 2020) [PMID:31931589]
_Worker-drafted node — pending editorial review._
Connections
efavirenz nightmare profile is a side effect of
Sources
- Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. (2013) pubmed
- Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events. (2014) pubmed
- Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom. (2020) pubmed
- Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis. (2014) pubmed
- Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. (2011) pubmed